1. Home
  2. ENTA vs SNCR Comparison

ENTA vs SNCR Comparison

Compare ENTA & SNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTA
  • SNCR
  • Stock Information
  • Founded
  • ENTA 1995
  • SNCR 2000
  • Country
  • ENTA United States
  • SNCR United States
  • Employees
  • ENTA N/A
  • SNCR N/A
  • Industry
  • ENTA Biotechnology: Pharmaceutical Preparations
  • SNCR EDP Services
  • Sector
  • ENTA Health Care
  • SNCR Technology
  • Exchange
  • ENTA Nasdaq
  • SNCR Nasdaq
  • Market Cap
  • ENTA 109.0M
  • SNCR 101.2M
  • IPO Year
  • ENTA 2013
  • SNCR 2006
  • Fundamental
  • Price
  • ENTA $5.09
  • SNCR $10.07
  • Analyst Decision
  • ENTA Buy
  • SNCR Strong Buy
  • Analyst Count
  • ENTA 4
  • SNCR 1
  • Target Price
  • ENTA $17.25
  • SNCR $13.00
  • AVG Volume (30 Days)
  • ENTA 503.4K
  • SNCR 57.1K
  • Earning Date
  • ENTA 02-18-2025
  • SNCR 03-11-2025
  • Dividend Yield
  • ENTA N/A
  • SNCR N/A
  • EPS Growth
  • ENTA N/A
  • SNCR N/A
  • EPS
  • ENTA N/A
  • SNCR N/A
  • Revenue
  • ENTA $67,635,000.00
  • SNCR $170,789,000.00
  • Revenue This Year
  • ENTA $8.11
  • SNCR $7.56
  • Revenue Next Year
  • ENTA N/A
  • SNCR $4.58
  • P/E Ratio
  • ENTA N/A
  • SNCR N/A
  • Revenue Growth
  • ENTA N/A
  • SNCR 61.81
  • 52 Week Low
  • ENTA $4.71
  • SNCR $5.83
  • 52 Week High
  • ENTA $17.80
  • SNCR $15.46
  • Technical
  • Relative Strength Index (RSI)
  • ENTA 38.07
  • SNCR 54.27
  • Support Level
  • ENTA $4.94
  • SNCR $9.02
  • Resistance Level
  • ENTA $5.31
  • SNCR $10.10
  • Average True Range (ATR)
  • ENTA 0.32
  • SNCR 0.66
  • MACD
  • ENTA 0.11
  • SNCR 0.05
  • Stochastic Oscillator
  • ENTA 39.05
  • SNCR 68.39

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

About SNCR Synchronoss Technologies Inc.

Synchronoss Technologies Inc is a leading provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and highly scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.

Share on Social Networks: